Michael R. Megna - 04 Oct 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
04 Oct 2024
Net transactions value
-$2,007
Form type
4
Filing time
08 Oct 2024, 16:40:31 UTC
Previous filing
04 Sep 2024
Next filing
02 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +175 +0.66% 26,610 04 Oct 2024 Direct F1
transaction KNSA Class A Ordinary Share Tax liability $2,007 -82 -0.31% $24.48 26,528 04 Oct 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -175 -50% $0.000000 175 04 Oct 2024 Class A Ordinary Share 175 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.